Canal Winchester

Atopic dermatitis (AD) is a skin condition causing rash and itching due to skin inflammation. This research compares two treatments, upadacitinib and dupilumab, in children aged 2 to less than 12 years with moderate to severe AD who need systemic anti-inflammatory therapy. The study aims to assess side effects and changes in disease activity while participants receive these treatments. Participants will receive either upadacitinib as a daily oral tablet or oral solution for up to 160 weeks or dupilumab by subcutaneous injection following its approved schedule for 52 weeks. Some participants will be randomized to receive medium or low doses of upadacitinib or dupilumab injections every 2 or 4 weeks, with dosing and grouping based on disease severity, age, and prior treatment response. Throughout the study, participants will attend regular hospital or clinic visits for clinical exams, blood tests, side effect monitoring, and questionnaires to track treatment effects. Researchers will measure improvements in eczema severity, itch, quality of life, and record adverse events. Follow-up will continue for 30 days after upadacitinib and at least 12 weeks after dupilumab treatment ends to ensure safety and monitor long-term outcomes.

Researchers are evaluating the long-term safety of Deucravacitinib compared to Ustekinumab in adults with moderate-to-severe plaque psoriasis who have certain cardiovascular risk factors. This Phase 3b/4 randomized, open-label study aims to assess cardiovascular and other safety outcomes over several years to better understand risks associated with these treatments in this patient group. The study is sponsored by Bristol-Myers Squibb. Participants will be randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on designated days. The study is designed to compare these two treatments over a long-term period, including up to five years of follow-up for major cardiovascular events and other health outcomes related to psoriasis treatment. During the study, participants will undergo regular monitoring for cardiovascular events such as heart attacks, strokes, and revascularization procedures, as well as other serious health events including infections and malignancies. Researchers will also track changes in liver function and lipid levels. The total duration of participant involvement can last up to five years, with safety assessments extending up to 60 days after the last dose of study medication.